ReportWire

Tag: Charles River Laboratories International

  • What Makes Charles River Laboratories (CRL) an Investment Bet?

    [ad_1]

    Madison Investments, an investment advisor, released its “Madison Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The third quarter was difficult for the Small Cap Fund.  The small-cap index’s performance was broad-based. The Madison Small Cap Fund (class Y) was down 1.3% in the quarter, significantly underperforming the benchmarks. The underperformance was driven by stock selection and exacerbated by a very speculative market. In addition, please check the fund’s top five holdings to know its best picks in 2025.

    In its third-quarter 2025 investor letter, the Madison Small Cap Fund highlighted stocks such as Charles River Laboratories International, Inc. (NYSE:CRL). Charles River Laboratories International, Inc. (NYSE:CRL) offers drug discovery, non-clinical development, and safety testing services that operate through Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing) segments. The one-month return of Charles River Laboratories International, Inc. (NYSE:CRL) was -14.15%, and its shares lost 16.72% of their value over the last 52 weeks. On November 21, 2025, Charles River Laboratories International, Inc. (NYSE:CRL) stock closed at $167.64 per share, with a market capitalization of $8.25 billion.

    Madison Small Cap Fund stated the following regarding Charles River Laboratories International, Inc. (NYSE:CRL) in its third quarter 2025 investor letter:

    “We initiated a position in Charles River Laboratories International, Inc. (NYSE:CRL) in Q3. CRL is a high-quality company in the drug discovery and development outsourcing space with a broad range of services from basic research to contract manufacturing. The company has operating margins of 20% or more and generates substantial free cash flow. The past few years have been challenging for companies in the drug development space, as capital has become increasingly constrained and research and development spending has remained stagnant. However, CRL has the operating history and mix of businesses to be successful over the long term. The customer base is diverse and CRL benefits from the increased dynamics of outsourcing by its biopharmaceutical clients. The company’s top line has grown at a 12% compound annual rate over the last 10 years, even with the recent downturn. Management is solid, and we’ve known them for decades. We believe Charles River’s earnings power can reach approximately $15 in 2028, assuming modest growth. We also use a sum of the parts at ~12x EBITDA (earnings before interest, taxes, depreciation, and amortization) to assess the attractiveness of CRL. This implies an intrinsic value of $228. Importantly, we think we are being conservative, as we don’t build in a resumption of double-digit revenue growth in our valuation framework. However, we anticipate revenue growth of 4% from 2024 to 2028 and a modest margin recovery, aided by restructuring and cost-outs.”

    Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025

    Charles River Laboratories International, Inc. (NYSE:CRL) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 49 hedge fund portfolios held Charles River Laboratories International, Inc. (NYSE:CRL) at the end of the second quarter, compared to 39 in the previous quarter. Charles River Laboratories International, Inc. (NYSE:CRL) reported revenue of $1 billion in the third quarter of 2025, a 0.5% decrease from Q3 2024. While we acknowledge the potential of Charles River Laboratories International, Inc. (NYSE:CRL) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    In another article, we covered Charles River Laboratories International, Inc. (NYSE:CRL) and shared ClearBridge Growth Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

    READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

    Disclosure: None. This article is originally published at Insider Monkey.

    [ad_2]

    Source link

  • Louisiana State Employees Retirement System Sells 100 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

    Louisiana State Employees Retirement System Sells 100 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

    [ad_1]

    Louisiana State Employees Retirement System decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.0% during the 2nd quarter, Holdings Channel reports. The firm owned 3,200 shares of the medical research company’s stock after selling 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Charles River Laboratories International were worth $673,000 at the end of the most recent reporting period.

    Several other large investors have also made changes to their positions in CRL. Moneta Group Investment Advisors LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $298,877,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Charles River Laboratories International by 35.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after purchasing an additional 653,790 shares during the last quarter. Norges Bank bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $97,675,000. Southpoint Capital Advisors LP bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth about $80,728,000. Finally, Clearbridge Investments LLC grew its holdings in shares of Charles River Laboratories International by 28.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock worth $388,739,000 after purchasing an additional 301,159 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

    Charles River Laboratories International Stock Performance

    Charles River Laboratories International stock opened at $195.62 on Wednesday. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. Charles River Laboratories International, Inc. has a 1 year low of $181.22 and a 1 year high of $262.00. The company has a market cap of $10.03 billion, a PE ratio of 20.74, a PEG ratio of 1.96 and a beta of 1.33. The company’s 50-day moving average is $202.47 and its two-hundred day moving average is $201.57.

    Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.06. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.77 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.49 earnings per share for the current year.

    Wall Street Analysts Forecast Growth

    CRL has been the topic of several analyst reports. Bank of America lowered their target price on shares of Charles River Laboratories International from $245.00 to $230.00 in a report on Friday, September 22nd. StockNews.com began coverage on shares of Charles River Laboratories International in a report on Thursday, October 5th. They set a “hold” rating on the stock. Guggenheim decreased their price objective on shares of Charles River Laboratories International from $255.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, September 22nd. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, August 10th. Finally, TD Cowen decreased their price objective on shares of Charles River Laboratories International from $212.00 to $209.00 and set a “market perform” rating on the stock in a report on Monday, September 25th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $237.09.

    Get Our Latest Analysis on Charles River Laboratories International

    Insider Activity at Charles River Laboratories International

    In related news, EVP Joseph W. Laplume sold 700 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the sale, the executive vice president now directly owns 24,983 shares in the company, valued at approximately $5,409,319.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Joseph W. Laplume sold 700 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the sale, the executive vice president now directly owns 24,983 shares in the company, valued at approximately $5,409,319.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP William D. Barbo sold 5,763 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $217.24, for a total transaction of $1,251,954.12. Following the completion of the sale, the vice president now owns 3,592 shares in the company, valued at $780,326.08. The disclosure for this sale can be found here. Insiders have sold 7,934 shares of company stock worth $1,722,048 in the last ninety days. Company insiders own 1.30% of the company’s stock.

    Charles River Laboratories International Company Profile

    (Free Report)

    Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

    Recommended Stories

    Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).

    Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

    Receive News & Ratings for Charles River Laboratories International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Charles River Laboratories International and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link